News
The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.
NEW YORK – Kelonia Therapeutics this week said it has started treating patients with relapsed and refractory multiple myeloma in a Phase I trial of its in vivo CAR T-cell therapy KLN-1010.
NEW YORK – Krystal Biotech has discontinued a Phase I/II clinical trial evaluating an injected version of its gene therapy KB707 in locally advanced or metastatic solid tumors, including melanoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results